NCT04530409.

Study name	Timing of corticosteroids in COVID‐19
Methods	Randomised controlled trial
Participants	Adult participants with mild or moderate COVID‐19 Included  Any case with COVID‐19 more than or equal to 18 years Mild and moderate severity Excluded Any contraindication to steroids Mental disability Planned sample size: 450 patients
Interventions	Intervention: "Early dexamethasone use as early as confirmation of inflammation"  Comparator: "Late dexamethasone use as soon as deterioration"
Outcomes	Outcomes of interest in the review: Primary outcomes: Presence of normal olfactory function Time to recovery from anosmia  (no further details provided) Serious adverse effects  Not reported Change in sense of smell Not reported Secondary outcomes: Prevalence of parosmia Not reported Change in sense of taste Not reported Disease‐related quality of life Not reported Other adverse effects (including nosebleeds/bloody discharge) Not reported Other outcomes reported by the study: Primary: Percentage of cases that will need hospitalisation Percentage of cases that deteriorate to acute respiratory distress syndrome  Secondary: Percentage of cases with increased d‐dimer  Time to recovery of diarrhoea Percentage reduction in CRP  Percentage reduction in LDH  Percentage reduction in ALT  Percentage reduction in ferritin Time to recovery of lymphopenia Time to recovery of cough Time to recovery of fever Time to recovery of myalgia Time to recovery of dyspnoea
Starting date	26 August 2020
Contact information	Emad R Issak Email: dr.emad.r.h.issak@gmail.com
Notes	Estimated study completion date: 1 December 2020  Trial registered in Egypt  Uncertainty over future inclusion in the review: It is not clear from the description provided whether participants will all have olfactory dysfunction at baseline and, if so, whether they will have ≤ 4 weeks of olfactory dysfunction.